- Report
- July 2023
- 3600 Pages
United States
From €8239EUR$9,000USD£7,002GBP
- Report
- January 2024
- 189 Pages
Global
From €4257EUR$4,650USD£3,618GBP
- Report
- January 2024
- 483 Pages
Global
From €6545EUR$7,150USD£5,563GBP
- Report
- September 2023
- 150 Pages
Africa
From €5447EUR$5,950USD£4,629GBP
- Report
- February 2023
- 120 Pages
Global
From €5447EUR$5,950USD£4,629GBP
- Report
- March 2024
- 78 Pages
Global
From €4531EUR$4,950USD£3,851GBP
- Report
- May 2022
- 290 Pages
Global
From €2197EUR$2,400USD£1,867GBP
- Report
- June 2023
- 71 Pages
Global
From €4531EUR$4,950USD£3,851GBP
- Report
- April 2024
- 123 Pages
Global
From €3616EUR$3,950USD£3,073GBP
- Report
- November 2023
- 30 Pages
Global
From €2975EUR$3,250USD£2,528GBP
- Drug Pipelines
- July 2023
- 30 Pages
Global
From €2975EUR$3,250USD£2,528GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2975EUR$3,250USD£2,528GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2975EUR$3,250USD£2,528GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2975EUR$3,250USD£2,528GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2975EUR$3,250USD£2,528GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2975EUR$3,250USD£2,528GBP
- Report
- August 2022
- 30 Pages
Global
From €2975EUR$3,250USD£2,528GBP
- Report
- August 2022
- 30 Pages
Global
From €2975EUR$3,250USD£2,528GBP
- Report
- August 2022
- 30 Pages
Global
From €2975EUR$3,250USD£2,528GBP
- Report
- August 2022
- 30 Pages
Global
From €2975EUR$3,250USD£2,528GBP

The Orphan Drug market is a subset of the Pharmaceutical industry that focuses on the development and commercialization of drugs for rare diseases. These drugs are typically developed to treat diseases that affect fewer than 200,000 people in the United States. The Orphan Drug Act of 1983 was passed to incentivize the development of these drugs by providing tax credits, grants, and other incentives to companies that develop them.
The Orphan Drug market has grown significantly in recent years, with more companies entering the market and more drugs being developed. This growth has been driven by advances in medical technology, increased public awareness of rare diseases, and the availability of government incentives.
Some companies in the Orphan Drug market include AbbVie, Amgen, Biogen, Gilead Sciences, and Novartis. Show Less Read more